BACKGROUND: Omentin-1 is an anti-inflammatory adipokine produced preferentially by visceral adipose tissue. Plasma levels of omentin-1 are decreased in obesity and other insulin-resistant states. Insulin resistance contributes to the changes of cholesterol synthesis and absorption as well. The aim of this study was to characterise omentin-1 plasma levels in obese patients with diabetes mellitus type 1 during weight reduction, and to elucidate the relationship between cholesterol metabolism and omentin-1. METHODS: Plasma levels of omentin-1 were measured in obese type 1 diabetics (n=14, body mass index >30 kg m(-2), age 29-62 years) by enzyme-linked immunosorbent assay (BioVendor). Gas chromatography with flame ionisation detector (Fisons Plc.,) was used to measure squalene and non-cholesterol sterols-markers of cholesterol synthesis and absorption (phase I). Measurements were repeated after 1 month (phase II; 1 week of fasting in the hospital setting and 3 weeks on a diet containing 150 g saccharides per day) and after 1 year (phase III) on a diet with 225 g saccharides per day. RESULTS: Omentin-1 plasma levels were stable during phases I and II, but significantly increased (P<0.001) during phase III. Omentin-1 plasma dynamics were significantly associated with plasma levels of high-density lipoprotein (P=0.005) and triacylglycerols (P=0.01), as well as with lathosterol (P=0.03). CONCLUSION: Omentin-1 plasma levels significantly increased during the weight reduction programme. Omentin-1 plasma dynamics suggest a close relationship with cholesterol metabolism.

3rd Department of Internal Medicine University Hospital in Hradec Králové Hradec Králové5 Czech Republic

Centre for Research and Development University Hospital in Hradec Králové Hradec Králové Czech Republic

Department of Clinical Biochemistry University Hospital in Hradec Králové Hradec Králové5 Czech Republic

Medical Faculty in Hradec Králové Charles University Prague Hradec Králové1 Czech Republic

Zobrazit více v PubMed

1Conway B, Miller RG, Costacou T, FriedL, Kelsey S, Evans RW et al. Temporal patterns in overweight and obesity in Type 1 diabetes. Diabet Med 2010; 27: 398–404. PubMed PMC

2Browne D, Meeking D, Shaw K, Cummings M. Endothelial dysfunction and pre-symptomatic atherosclerosis in type 1 diabetes, pathogenesis and identification. Br J Diabetes Vasc Dis 2003; 3: 27–34.

3Tan B K, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity and cardiovascular disease. Trends Cardiovasc Med 2010; 20: 143–148. PubMed

4Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008; 14: 741–751. PubMed PMC

5Lago F, Gómez R, Gómez-Reino JJ, Dieguez C, Gualillo O. Adipokines as novel modulators of lipid metabolism. Trends Biochem Sci 2009; 34: 500–510. PubMed

6Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253–1261. PubMed

7De Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655–1661. PubMed

8Chen H, Montagnani M, Funahashi T, Shimomura I, Quon M J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021–45026. PubMed

9Stejskal D, Ruzicka V, Adamovska S, Jurakova R, Proskova J, Jedelsky L et al. Adiponectin concentrations as a criterion of metabolic control in persons with type2 diabetes mellitus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003; 147: 167–172. PubMed

10Tan B K, Adya R, Farhatullah S, Lewandowski K C, Hare P O, Lehnert H et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome. Ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57: 801–808. PubMed

11Yilmaz Y, Yonal O, Kurt R, Alhdab YO, Eren F, Ozdogan O et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011; 46: 91–97. PubMed

12Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, Randeva HS. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 2010; 59: 3023–3031. PubMed PMC

13Tsuji S, Uehori J, Matsumoto M, Suzuki Y, Matsuhisa A, Toyoshima K et al. Human intelectin is a novel soluble lectin that recognises galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem 2001; 276: 23456–23463. PubMed

14Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011; 408: 339–343. PubMed

15Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilatation in rat isolated blood vessels. Biochem Biophys Res Commun 2010; 393: 668–672. PubMed

16Duan XY, Xie PL, Ma YL, Tang SY. Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. Amino Acids 2011; 41: 1223–1231. PubMed

17Tan BK, Pua S, Syed F, Lewandowski KC, O'Hare JP, Randeva HS. Decreased plasma omentin-1 levels in diabetes mellitus Type 1. Diabet Med 2008; 25: 1254–1255. PubMed

18Simonen P, Gylling H, Howard A, Miettinen T A. Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am J Clin Nutr 2000; 72: 82–88. PubMed

19Šmahelová A, Zadák Z, Hyšpler R, Haas T. An importance of vegetable sterols in diabetics (in Czech). Vnitř Lék 2004; 50: 147–152. PubMed

20Moreno-Navarrete J M, Catalán V, Ortega F, Gómez-Ambrosi J, Ricart W, Frühbeck G et al. Circulating omentin concentration increases after weight loss. Nutr Metab 2010; 7: 27. PubMed PMC

21Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull 2011; 34: 307–310. PubMed

22Auget T, Quintero Y, Riesco D, Morancho B, Terra X, Crescenti A et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 2011; 12: 60. PubMed PMC

23Pan HY, Guo L, Li Q. Changes in serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clinical Prac 2010; 88: 29–33. PubMed

24Yan P, Liu D, Long M, Ren Y, Pang J, Li R. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 257–263. PubMed

25Saremi A, Ascghari M, Ghorbani A. Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. J Sports Sci 2010; 28: 993–998. PubMed

26Barth S, Klein P, Horbach T, Dotsch J, Rauh M, Rascher W et al. Expression of Neuropeptide Y, Omentin and Visfatin in Visceral and Subcutaneous Adipose Tissues in Humans: Relation to Endocrine and Clinical Parameters. Obes Facts 2010; 3: 245–251. PubMed PMC

27Moreno-Navarrete Jmm, Ortega F, Castro A, Sabater M, Ricart W, Fernández-Real JM. Circulating Omentin as a Novel Biomarker of Endothelial Dysfunction. Obesity (Silver Spring) 2011; 19: 1552–1559. PubMed

28Ji-Yin Z, Ch Lawrence, Shi-Wen Z., Omentin. Linking Metabolic Syndrome and Cardiovascular Disease. Curr Vasc Pharmacol 2014; 12: 136–143. PubMed

29Yu D. Omentin activates AMP – activated protein kinase and plays a role in energy metabolism and immune response. PhD dissertation. Molecular Medicine. University of Maryland, Baltimore, MD, USA, 2011..

30Kataoka Y, Shibata R, Ohashi K, Kambara T, Enomoto T, Uemura Y et al. Omentin prevents myocardial ischaemic injury through AMP- activated protein kinase – and Akt-dependent mechanisms. J Am Coll Cardiol 2014; 63: 2722–2733. PubMed